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ORIGINAL ARTICLE
Topical nicotinamide for seborrheic dermatitis: an open randomized
study
Gabriella Fabbrocini, Mariateresa Cantelli & Giuseppe Monfrecola
Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli Federico II, Naples, Italy
Background: Treatment of seborrheic dermatitis (SD) includes
various options with different success and safety limitations.
Objective: To evaluate the efﬁcacy of topical nicotinamide (NCT)
in the treatment of SD. Methods: A total of 48 patients with mild
to moderate SD of the face were enrolled in the study (36 males
and 12 females; age 20–50 years). Patients were randomized into
two groups A and B, who were treated once a day with topical
administration of NCT 4% cream and with the vehicle without
NCT (placebo), respectively. Clinical measures were assessed by
erythema, scaling, and inﬁltration, which were evaluated using a
four-point scale 0–3 before starting treatment and after 2, 6, and
12 weeks’ therapy. Results: In comparison with baseline, a
reduction of 75% of the total score was observed in patients
treated with NCT, whereas for placebo-treated patients the
reduction was of 35% (p < 0.05). Conclusion: Topical NCT 4%
can have a potential for the treatment of SD.
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Introduction
Seborrheic dermatitis (SD) is a common inﬂammatory dermatosis
that may affect infants, adolescents, and adults of all ethnicities
(1,2). SD is characterized by the appearance of red, ﬂaking, greasy
areas of skin, most commonly on the nasolabial folds, ears,
eyebrows, and chest; the scales are greasy. Its pathogenesis is
linked to different species of Malassezia but also to other
unknown factors (3). For its complex pathogenesis, various
treatment options are available: antifungal preparations, topical
steroids, and keratolytics (4–10).
Nicotinamide (NCT), the amide derivative of vitamin B3, alone
or in combination with tetracycline antibiotics, has been assessed
in numerous clinical studies for the treatment of inﬂammatory
dermatologic condition such as acne vulgaris (11), acne rosacea,
and bullous pemphigoid (12). In this open randomized study, we
aimed to evaluate the efﬁcacy and safety of NCT in the treatment
of SD.
Materials, patients and methods
Patients
Forty-eight patients (36 males and 12 females; aged 20–50 years)
with mild to moderate SD, attending our outpatient dermatology
clinic, were included in the study. All patients provided written
informed consent prior to study enrollment. Coexistent psoriasis,
rosacea, and acne vulgaris or any other dermatoses involving the
face or other affected area and allergy to medications were criteria
for exclusion. Patients who had used any topical and systemic
treatments in the previous 1 month were excluded.
Study design
The study was conducted from October 2010 through February
2012. Patients were randomly divided into two treatment groups.
The ﬁrst group was treated with NCT 4% cream containing
sphingolipids as a vehicle, whereas the second received a placebo
cream (the same vehicle without NCT). Patients were instructed
to treat the affected areas once a day. The area was cleansed and
then the cream was applied. No other medications or cosmetics
for SD were allowed during the trial. The study was approved by
the Institutional Review Board.
Efﬁcacy assessment
Patients were evaluated by two different investigators (GM and
VC). At the initial evaluation, patients were examined and lesions
graded numerically for erythema, scaling, and inﬁltration using a
four-point scale from 0 to 3 (0 = none, 1 = mild, 2 =moderate, 3 =
severe) as previously used by Koc et al. (13). Patients were
examined before treatment and at 2, 6, and 12 weeks, and were
asked to report any adverse effects from the medications. All
adverse effects such as pruritus, burning sensation, erythema,
and others were noted and recorded. Digital photographs were
taken with the same camera settings and lighting conditions
(Reveal Imager, Canﬁeld Imaging Systems, 253 Passaic Avenue,
Fairﬁeld, NJ, USA) before treatment and at 2, 6, and 12 weeks (13).
Statistical analysis
Nonparametric Wilcoxon test was performed to assess if the
independent ordinal samples evaluated satisfy the null hypothesis
(H0): P(X>Y) = 0.5 or alternative hypothesis (H1): P(X>Y) = 0.5.
This test is a nonparametric statistical hypothesis test used when
comparing two related samples, matched samples, or repeated
measurements on a single sample to assess whether their population
mean ranks differ (i.e., it is a paired difference test).
Results
Patients
The ﬁrst group (24 patients) was treated with NCT and the
second one (24 patients) with topical placebo. A ﬂowchart of
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the study is shown in Figure 1. Twenty patients in the NCT
group and 19 patients in the placebo group completed the
treatment period . Five patients in both groups left the study
(Figure 1). The study focused on the main signs of SD: erythema,
scaling, and inﬁltration. The total score of the three signs that we
evaluated in the treated group was compared with that in the
control one. In the group treated with NCT, there was a 75%




Lost after baseline evaluation n = 2
Received treatment and included in
the analysis n = 22
Discontinued n = 2
Lost to follow up n = 2
Lack of efficacy n = 0
Side effects n = 2
Discontinued n = 3
Lost to follow up n = 2
Lack of efficacy n = 0
Side effects n = 0
Completed treatment n = 20 Completed treatment n = 19
Nicotinamide group n = 24 Placebo group n = 24
Lost after baseline evaluation n = 3
Received treatment and included in
the analysis n = 21
Assessed for eligibility n = 48
Randomized n = 48
Excluded n = 0
Figure 1. Flowchart of the study.
A B
Figure 2. Patient 1 before (A) and after (B) a topical NCT treatment. NCT = nicotinamide.





















































(Figures 2 and 3). In the control group, there was a 35% decrease
of the total score of all signs mainly due to a reduction of scaling
because of the presence of glycosphingolipids in placebo cream.
Other signs, erythema and inﬁltration, were not changed during
treatment with placebo.
Compliance of the therapy
Among patients who concluded the study (81.25%), none referred
to avoid the application during the period of therapy. None
referred to have side effects that obliged them to suspend the
treatment.
Treatment efﬁcacy
In comparison with baseline, in the group treated with NCT,
there was a statistically signiﬁcant decrease in erythema, scaling,
and inﬁltration criteria (p < 0.05) and there was a higher
reduction of signs (75% vs. 35%) in patients treated with
NCT (Table I) with respect to patients treated with placebo
(Table II). The reduction in scores within each group between
baseline and week 12 was statistically signiﬁcant according to
the Wilcoxon signed-rank test.
Side effects
Adverse events were observed in two patients in the NCT group.
Adverse events include minimal burning sensation and pruritus.
No adverse events were observed in the placebo group.
Discussion
Literature shows that NCT can regulate cellular inﬂammation
(14). In fact, NCT blocks proinﬂammatory cytokines, such as
interleukin (IL)-1b, IL-6, IL-8, tissue factor, and tumor necrosis
factor (TNF)-a (15–18), as well as transforming growth factor
(TGF)-b2 and macrophage chemotactic protein-1 in hepatic cells
(19). Ungerstedt et al. demonstrate that NCT has the capacity to
downregulate, dose dependently, the cytokine response with a
therapeutic potential as a modulator of cytokine effects in inﬂam-
matory disease (18). Our results suggest that NCT can modulate
A B
Figure 3. Patient 2 before (A) and after (B) a topical NCT treatment. NCT = nicotinamide.
Table I. Data scores from NCT treatment group at time 0 and time 12.
Before treatment (week 0) After treatment (week 12)
Patients Erythema Scaling Inﬁltration
Total score
before treatment Erythema Scaling Inﬁltration
Total score at the
end of the treatment
1 3 2 1 6 2 0 0 2
2 2 2 1 5 0 1 0 1
3 3 2 1 6 1 1 0 2
4 2 2 2 6 0 0 1 1
5 3 3 1 7 1 0 1 2
6 3 2 1 6 1 0 0 1
7 3 3 2 8 1 1 0 2
8 2 1 1 4 0 0 1 1
9 3 2 2 7 1 1 0 2
10 2 2 2 6 0 0 1 1
11 2 2 1 5 1 1 0 2
12 3 2 1 6 1 1 0 2
13 2 2 1 5 0 1 0 1
14 3 2 1 6 1 0 0 1
15 2 2 1 5 1 0 0 1
16 2 2 1 5 0 1 0 1
17 2 3 1 6 1 0 0 1
18 3 2 2 7 1 0 0 1
19 3 1 1 5 1 0 0 1
20 2 2 1 5 1 0 0 1
NCT = nicotinamide.





















































the cytokine effects on inﬂammatory disease. Dougherty et al.
support the hypothesis that NCT could inhibit the production of
TNF-a and the inﬂammatory response to induce apoptosis via
inhibition of nuclear factor-kappa B (NF-kB) that has a protective
role versus apoptotic process and its inhibition can lead to
apoptosis (20). NCT seems to inhibit poly(ADP-ribose) polymer-
ase (PARP) (20). The PARP superfamily consists of 17 members,
with some of them implicated in the regulation of the immune
response. They have been described to inﬂuence inﬂammatory
processes through modulating different transcription factors
(21,22). PARP-1 in fact interacts with a large number of proin-
ﬂammatory transcription factors and is known to be involved in
the pathogenesis of some inﬂammatory skin diseases like acne
(23). The beneﬁcial effects of PARP-1 ablation on inﬂammatory
damage have been shown in multiple disease models such as
colitis, arthritis, uveitis, pancreatitis (24) and some inﬂammatory
dermatoses. PARP inhibitors prevented necrotic cell death with a
slight increase in apoptotic DNA fragmentation and also reduced
cytokine-induced expression of IL-8 and intercellular adhesion
molecule 1 (ICAM-1) in human keratinocyte cell line (HaCaT)
cells (25). Furthermore, the inhibition of PARP by NCT can
explain the therapeutic effect of NCT on SD. Our results highlight
these properties. Moreover, Tanno et al. demonstrated that NCT
increases ceramides and other intercellular lipids in the stratum
corneum (SC), and suggests that NCT may play an important role
in the maintenance of the epidermal permeability barrier by
regulating SC intercellular lipids synthesis (26). The control of
the inﬂammatory cascade by NCT can explain the signiﬁcant
reduction of SD symptoms showed in our study and can suggest
NCT as an optional therapy for SD.
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